Dokter Imunoterapi dengan Keytruda (Pembrolizumab) terbaik di luar negeri — Halaman 3

Dr. Emad Shash adalah seorang onkolog medis yang telah berpartisipasi dalam lebih dari 70 uji klinis onkologi. Beliau menjabat sebagai Direktur Medis Rumah Sakit Kanker Payudara Komprehensif di NCI. Dr. Shash berspesialisasi dalam terapi sistemik, termasuk kemoterapi, terapi target, dan imunoterapi. Beliau memegang Diploma dalam Manajemen Kualitas Rumah Sakit dan Keselamatan Pasien dari JCI.

• Berperan sebagai anggota panel pemungutan suara ESMO dan anggota komite ASCO.
• Menangani kanker payudara, ginekologi, genitourinari, toraks, gastrointestinal, dan kanker langka.
• Mantan dokter peneliti dan pimpinan medis di EORTC di Brussels.
• Bekerja di Shefaa Al Orman, pusat onkologi terakreditasi ESMO yang menangani 6.000 pasien setiap tahun.

Dr. Raanan Berger adalah Direktur Pusat Kanker di Sheba Medical Center. Beliau masuk dalam daftar "Dokter Terbaik" Forbes Israel pada tahun 2025. Dr. Berger berspesialisasi dalam onkologi genitourinari dan melakukan radioterapi pada tumor prostat yang kompleks. Beliau menyelesaikan fellowship pascadoktoral di Dana-Farber/Harvard Cancer Institute.

• Memimpin unit penelitian klinis yang berfokus pada onkologi molekuler.
• Penulis bersama lebih dari 20 makalah yang ditinjau sejawat tentang kanker prostat dan mutasi BRCA.
• Anggota American Society of Clinical Oncology (ASCO).
• Melakukan terapi sistemik dan radioterapi di rumah sakit yang masuk dalam peringkat 10 besar dunia.

Dr. Maha Yahia adalah onkolog medis dan hematolog di Shefaa Al Orman International Oncology Hospitals. Beliau pernah bertugas sebagai dokter dengan pangkat Letnan Kolonel di Korps Medis Angkatan Bersenjata Mesir. Dr. Yahia berspesialisasi dalam perencanaan perawatan untuk kanker payudara, toraks, dan gastrointestinal. Beliau berfokus pada imunoterapi, terapi target, dan protokol kemoterapi yang kompleks.

• Mantan Kepala Tim Pendukung Penelitian Klinis di Maadi AFMC.
• Terlatih di National Cancer Institute, Universitas Kairo, dalam bidang hemato-onkologi.
• Menangani kanker genitourinari, ginekologi, dan kanker langka serta kondisi hematologi.
• Bekerja di pusat terakreditasi ESMO yang menangani 6.000 pasien setiap tahun.

Dr. Jair Bar adalah ahli onkologi toraks dan Wakil Direktur Pusat Kanker di Sheba Medical Center. Beliau berspesialisasi dalam mengobati kanker paru-paru sel tidak kecil stadium lanjut menggunakan imunoterapi yang dipersonalisasi dan perawatan bertarget. Dr. Bar memegang gelar PhD dalam Biologi Molekuler dan memimpin laboratorium penelitian yang berfokus pada resistensi imunoterapi.

• Ketua Kelompok Kanker Paru-Paru Israel.
• Bersertifikat dalam Onkologi Medis dan Radioterapi Onkologi.
• Merawat pasien di Sheba Medical Center, salah satu dari 10 rumah sakit terbaik di dunia.
• Menggunakan profil molekuler dan genetik untuk membuat rencana perawatan kanker yang tepat.

Dr. Eytan Aharon Ben-Ami memimpin Divisi Onkologi di Sheba Medical Center di Israel. Beliau berspesialisasi dalam sarkoma dan onkologi tulang di Dana-Farber Cancer Institute. Dr. Ben-Ami mendirikan Sheba Clinical Research Organization untuk memajukan studi kanker. Beliau menangani tumor tulang langka dan sarkoma jaringan lunak dengan protokol yang dipersonalisasi.

• Memimpin Unit Uji Klinis Fase Awal untuk terapi kanker inovatif.
• Penulis lebih dari 40 publikasi ilmiah tentang mekanisme molekuler dan deteksi dini.
• Memimpin uji coba Fase I dalam terapi target dan imunoterapi untuk kanker langka.
• Bekerja di Sheba Medical Center, salah satu dari 10 rumah sakit terbaik di dunia menurut Newsweek.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Kepala Dokter Pusat Onkologi di Assuta Medical Center, yang berspesialisasi dalam perawatan imunoterapi.

• Onkolog dengan pengalaman luas dalam terapi target
• Memimpin tim khusus untuk perawatan kanker tingkat lanjut
• Berfokus pada rencana perawatan yang dipersonalisasi untuk pasien

Wakil Kepala Departemen Onkologi di Rambam Medical Center – Dr. Bar-Sela berspesialisasi dalam perawatan kanker mutakhir.

• Pakar imunoterapi dengan Keytruda (pembrolizumab)
• Berfokus pada rencana perawatan kanker yang dipersonalisasi
• Bekerja di departemen onkologi terkemuka di Israel

Spesialis terkemuka Israel dalam imunoterapi kanker paru-paru – Prof. Peled memimpin Unit Kanker Toraks di Davidoff Cancer Center.

• Pakar Penyakit Dalam, Pulmonologi, dan Onkologi Medis
• Penerima penghargaan ASCO MERIT untuk penelitian luar biasa
• Kepala Unit Penelitian dan Deteksi keganasan Toraks di Sheba Medical Center
• Ketua Komite Deteksi Dini & Pencegahan IASLC

Profesor Bosch memimpin penelitian global dalam pengobatan Leukemia Limfositik Kronis (CLL) dan limfoma, dengan lebih dari 80 uji klinis aktif.

• Spesialis limfoma dan CLL di Hospital Quiron Barcelona
• Telah menerbitkan lebih dari 100 artikel di jurnal terkemuka seperti NEJM dan Nature Medicine
• Kepala Hematologi di Rumah Sakit Universitas Vall d'Hebron
• Mengembangkan pendekatan terapeutik baru untuk gangguan limfoproliferatif

Dr. Weidmann memimpin sektor Hematologi di Klinik Nordwest dengan 36 tahun pengalaman dalam pengobatan kelainan darah.

• Spesialis dalam kasus limfoma non-Hodgkin
• Profesor dengan kualifikasi akademik yang luas
• Bekerja di Klinik Nordwest – pusat hematologi terkemuka

Prof. Madya Ayse Irem Yasin berspesialisasi dalam imunoterapi untuk berbagai jenis kanker di Rumah Sakit Distrik Medipol Acibadem, dengan keahlian dalam perawatan Keytruda.

• Bersertifikat ESMO – diakui karena standar tinggi dalam onkologi
• Pelatihan fellowship dalam Onkologi Medis di Universitas Bezmialem Vakif
• Berpengalaman dalam mengobati kanker paru-paru, payudara, dan gastrointestinal
• Observasi internasional di Italia dan AS meningkatkan praktiknya

Prof. Baytan berspesialisasi dalam onkologi anak dan hematologi, dengan pengalaman luas dalam perawatan leukemia dan limfoma.

• Lulusan Fakultas Kedokteran Universitas Ankara
• Menerbitkan 15 artikel di jurnal internasional
• Berspesialisasi dalam perawatan defisiensi zat besi dan vitamin
• Bekerja di Rumah Sakit Emsey

Prof. Dr. Serdar Bedii Omay memiliki lebih dari 65 artikel ilmiah di bidang hematologi dan transplantasi sumsum tulang, dengan pengalaman penelitian internasional yang luas.

• Spesialis hematologi dengan gelar PhD dari Mie Medical School, Jepang
• Profesor di Universitas Ege dan Universitas Teknik Karadeniz
• Lebih dari 34 presentasi konferensi di bidang tersebut

Profesor Madya Nail Paksoy berspesialisasi dalam imunoterapi di Rumah Sakit Medipol Bahçelievler, dengan pengalaman luas dalam uji klinis yang melibatkan Keytruda.

• Bersertifikat ESMO dalam Onkologi Medis
• Sub-peneliti dalam berbagai uji coba imunoterapi internasional
• Penelitian yang dipublikasikan tentang perawatan kanker tingkat lanjut
• Gelar ganda dalam Onkologi Medis dan Alergi-Imunologi

Prof. Dr. Gül Alço adalah ahli onkologi radiasi dengan pengalaman sekitar 27 tahun. Beliau menangani kanker payudara, paru-paru, prostat, saluran pencernaan, ginekologi, sistem saraf pusat, kepala dan leher, jaringan lunak, serta tulang dengan radioterapi.

Keahliannya meliputi radioterapi adaptif dan bedah radiasi (radiosurgery). Beliau menggunakan teknik radiasi canggih untuk memberikan perawatan yang dipersonalisasi dan berbasis bukti dalam lingkungan multidisiplin yang berpusat pada pasien.